1800 244 735

Helpline (02) 9874 9777

HD Service at Westmead approved to participate in 2 new drug trials

 

The Huntington Disease Service at Westmead Hospital has been approved to participate in two new drug trials, called PRECISION-HD1 and PRECISION-HD2. Each study tests a separate Huntingtin-lowering (also known as gene silencing) agent. They are run by a company called Wave Life Sciences based in Massachusetts, USA. The studies involve lumbar punctures, MRI scans, assessments and questionnaires.

These are Phase 1b/2a trials, meaning that they are testing an experimental treatment in humans for the first time. The main goal is to assess whether the treatments are safe and well tolerated in the treatment of Huntington’s disease when compared with a placebo control. Participants must be between the ages of 25-65, have early stage Huntington’s disease, and meet additional criteria.

The study has already commenced overseas. Information can be found at https://clinicaltrials.gov/ct2/show/NCT03225833?recrs=a&cond=huntington%27s+disease&draw=2&rank=16 and https://clinicaltrials.gov/ct2/show/NCT03225846?recrs=a&cond=huntington%27s+disease&draw=2&rank=15. It is expected that together the two studies will involve approximately 96 people worldwide.

If you would like more information, you can call the Huntington Disease Service at Westmead on 0456 740 612. The phone will be monitored on Mondays and Thursdays. Please leave a message if we do not answer when you call.

Huntington’s NSW & ACT and the Huntington Disease Service at Westmead will continue to provide updates on HD research through the Huntington’s NSW & ACT website and Facebook page

Share on facebook
Share on twitter
Share on pinterest
Share on email

Latest News and Stories

CHDI Foundation Postcards

Published date: 15 November, 2021

The Postcards are a series of short videos aimed at non-scientists that convey the major themes, scientific breakthroughs, and clinical trial updates from each year’s Huntington’s Disease.

Introducing Prof. Kenneth Serbin – guest speaker at AGM

Published date: 11 November, 2021

Kenneth P. Serbin’s mother Carol died of Huntington’s disease in 2006 after a 20-year battle against the disease. Serbin tested positive for the HD gene in 1999. His daughter Bianca tested negative for HD in the womb and is today a healthy 21-year-old college senior. Since 1998, Serbin has served as a volunteer advocate for ... Read more

HD Spotlight on Amy Hale

Published date: 2 November, 2021

Here from our Youth Social Worker, Amy Hale, on why she became a social worker, how she got involved in the HD world and what her ideal Sunday is.

HD News Spring 2021

Published date: 1 November, 2021

Download your copy of the HD News Spring 2021 here. We hope that you enjoy reading the latest news from Huntington's NSW ACT. If you have any feedback or questions please contact us at the office.
Carer opening a care hamper

Celebrating National Carers week

Published date: 28 October, 2021

Thank you @CarersNSW Our Carer Support groups received a donation from CarersNSW to help celebrate National Carers week (Sunday 10th Oct-Sat 16th Oct). Each region was planning to host an event for their Carer group but unfortunately COVID hijacked these plans. Instead carers of the Port Macquarie and Wollongong Support groups received a phone call, ... Read more

Accessible Product Design Alliance

Published date: 13 September, 2021

The Accessible Product Design Alliance is a group of not-for-profit consumer health organisations that represent people with chronic conditions who are significantly impacted by inaccessible products and packaging. The Alliance was formed in 2019 to advocate to government and industry to improve access to products and packaging that are easy to use for these consumers and to increase research in the area.